Search - tctmd.com

Displaying 21 - 40 of 153

Sort: Relevancy | Date

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

November 2022 News Roundup

News Opinion CV Team Dispatch

November 2022 News Roundup

November 01, 2022

Presentation Cardiovascular Interventions 2022

Do All Patients with New Onset HF Need Assessment for CAD?

Presenter: J. Thomas Heywood

October 28, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

News Daily News

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

October 17, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

News Daily News

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

Michael O'Riordan

September 26, 2022

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.